Highlights Valneva Xetra

Equities

Market Closed - Xetra Other stock markets 11:35:47 2024-06-13 am EDT			5-day change	1st Jan Change
3.486 ^EUR	-3.17%		-9.08%	-26.60%

Jun. 04	Pfizer: article on Lyme vaccine in The Lancet	CF
Jun. 04	Valneva: article on Lyme vaccine in The Lancet	CF

Pfizer: article on Lyme vaccine in The Lancet	Jun. 04	CF
Valneva: article on Lyme vaccine in The Lancet	Jun. 04	CF
Valneva SE Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases	Jun. 03	CI
Valneva's Chikungunya Vaccine Gains Support From EU Regulator Committee	May. 31	MT
Valneva SE Receives EMA?s Positive CHMP Opinion for its Chikungunya Vaccine	May. 31	CI
EU regulator recommends use of Valneva's chikungunya vaccine	May. 31	RE
Valneva: new positive data in CHIKV	May. 13	CF
Valneva SE Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Valneva: quarterly results boosted by PRV sale	May. 07	CF
Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024	May. 07	CI
Valneva: Deep Track Biotechnology Master holds less than 5% of the capital	Apr. 11	CF
Valneva Kicks Off Early-stage Trial for Zika Vaccine Candidate	Mar. 26	MT
Valneva: Phase 1 trial initiated in the Zika virus	Mar. 26	CF
Valneva SE Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate	Mar. 26	CI
ADRs End Higher; XTL Biopharmaceuticals Climbs 129%	Mar. 20	DJ
Valneva SE Raises Revenue Guidance for 2024	Mar. 20	CI
Valneva SE Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Valneva: share price down, forecasts below expectations	Mar. 20	CF
French biotech company Valneva raises product sales guidance	Mar. 20	RE
U.S. CDC Advisory Committee Recommends Use of Valneva?s Single-Dose Chikungunya Vaccine IXCHIQ	Feb. 29	CI

No results for this search